Literature DB >> 17064634

Adjunctive immunotherapy in combination with lipid-associated amphotericin B for the treatment of invasive candidiasis.

Stanley Chapman.   

Abstract

Entities:  

Year:  2006        PMID： 17064634     DOI： 10.1007/s11908-006-0015-7

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.725


× No keyword cloud information.
  9 in total

1.  Candidemia is costly--plain and simple.

Authors:  Scott K Fridkin
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

2.  The third age of antimicrobial therapy.

Authors:  Arturo Casadevall
Journal:  Clin Infect Dis       Date:  2006-04-12       Impact factor: 9.079

3.  Dynamic activation of endothelial nitric oxide synthase by Hsp90.

Authors:  G García-Cardeña; R Fan; V Shah; R Sorrentino; G Cirino; A Papapetropoulos; W C Sessa
Journal:  Nature       Date:  1998-04-23       Impact factor: 49.962

4.  The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis.

Authors:  Theoklis E Zaoutis; Jesse Argon; Jaclyn Chu; Jesse A Berlin; Thomas J Walsh; Chris Feudtner
Journal:  Clin Infect Dis       Date:  2005-09-20       Impact factor: 9.079

5.  Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII.

Authors:  Kusumam Joseph; Baby G Tholanikunnel; Allen P Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-15       Impact factor: 11.205

Review 6.  Adjunctive immune therapy for fungal infections.

Authors:  A Casadevall; L A Pirofski
Journal:  Clin Infect Dis       Date:  2001-08-22       Impact factor: 9.079

7.  Attributable mortality of nosocomial candidemia, revisited.

Authors:  Olafur Gudlaugsson; Shane Gillespie; Kathleen Lee; Jeff Vande Berg; Jianfang Hu; Shawn Messer; Loreen Herwaldt; Michael Pfaller; Daniel Diekema
Journal:  Clin Infect Dis       Date:  2003-10-08       Impact factor: 9.079

8.  A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

Authors:  John H Rex; Peter G Pappas; Adolf W Karchmer; Jack Sobel; John E Edwards; Susan Hadley; Corstiaan Brass; Jose A Vazquez; Stanley W Chapman; Harold W Horowitz; Marcus Zervos; David McKinsey; Jeannette Lee; Timothy Babinchak; Robert W Bradsher; John D Cleary; David M Cohen; Larry Danziger; Mitchell Goldman; Jesse Goodman; Eileen Hilton; Newton E Hyslop; Daniel H Kett; Jon Lutz; Robert H Rubin; W Michael Scheld; Mindy Schuster; Bryan Simmons; David K Stein; Ronald G Washburn; Linda Mautner; Teng-Chiao Chu; Helene Panzer; Rebecca B Rosenstein; Jenia Booth
Journal:  Clin Infect Dis       Date:  2003-05-08       Impact factor: 9.079

9.  Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90.

Authors:  Ruth C Matthews; Gordon Rigg; Samantha Hodgetts; Tracey Carter; Caroline Chapman; Carl Gregory; Chris Illidge; James Burnie
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.